Cart
sales@molnova.com
Pipoxizine
CAS No. 55837-21-3
Pipoxizine( —— )
Catalog No. M36111 CAS No. 55837-21-3
Pipoxizine has an antagonistic effect on histamine-induced bronchoconstriction and may be used in the study of asthma disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 247 | In Stock |
|
| 10MG | 371 | In Stock |
|
| 25MG | 620 | In Stock |
|
| 50MG | 863 | In Stock |
|
| 100MG | 1172 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2353 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePipoxizine
-
NoteResearch use only, not for human use.
-
Brief DescriptionPipoxizine has an antagonistic effect on histamine-induced bronchoconstriction and may be used in the study of asthma disease.
-
DescriptionPipoxizine has an antagonistic effect on histamine-induced bronchoconstriction and may be used in the study of asthma disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number55837-21-3
-
Formula Weight381.51
-
Molecular FormulaC24H31NO3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(=C1CCN(CCOCCOCCO)CC1)(C2=CC=CC=C2)C3=CC=CC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Phenyl-ac-Gly-OH
Phenylacetylglycine is an acyl glycine. Acyl glycines are normally minor metabolites of fatty acids. The presence of phenylacetylglycine in urine has been confirmed for dogs rats and mice. However the presence of this compound in human urine is controversial. GC-MS studies have not found this compound while NMR studies claimed to have identified it.
-
Coelenterazine h
Coelenterazine H is a synthetic derivative of coelenterazine (a light-emitting biomolecule).
-
BMS-593214
BMS-593214 is an active site-directed factor (F) VIIa inhibitor that exhibits antithrombotic and antihaemostatic properties.
